arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

uniQure N.V.

QURE
$21.00 ▼ -2.07 (-8.97%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
13 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

uniQure N.V. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2B
Dividend Yield —
Revenue Growth -40.6% ↘
Op. Margin None
ROIC -70.4% ↗
FCF / Share $-3.10 ↗
Trailing P/E —
Price / Book 6.6x
FCF Yield —
Debt / Equity 0.36
info Valuation on last close. End-of-day price, Nov 5, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$16.10M
↓ -40.6% —
Net Income Profit after all expenses
$-198.97M
↑ +16.9% —
Operating Margin Operating profit as % of sales
-134.4%
↓ -326.8% —
FCF / Share Free cash flow per share
$-3.10
↑ +18.9% —
Long-Term Debt Long-term obligations
$71.92M
↑ +40.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
9
Financial Health ↑
46
Cash Quality ↑
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 44 quarters